Limes Schlosskliniken AG

Research Limes Schlosskliniken AG (LIK) on Bullrun: market cap EUR 162.38M, P/E 28.5, dividend yield 1.8%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 162.38M; P/E is 28.5; dividend yield is 1.8%.

Peer valuation comparison

Latest P/E is 28.55x versus a Healthcare sector median of 24.46x (16.7% above).

Latest dividend yield is 1.79% versus a Healthcare sector median of 2.11% (15.2% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 50.00MEUR 5.69MEUR 1.14M91.9%19.11EUR 10.31MEUR 10.73MEUR 25.31M
FY2024EUR 37.45MEUR 3.11MEUR 2.48M92.1%10.61EUR 10.88MEUR 10.48MEUR 18.33M
FY2023EUR 37.17MEUR 3.40M-EUR 3.51M90.8%11.58EUR 8.52MEUR 10.09MEUR 15.13M
FY2022EUR 28.81MEUR 4.20MEUR 6.69M90.2%14.34EUR 10.93MEUR 9.04MEUR 11.10M
FY2021EUR 23.43MEUR 3.94M-EUR 1.60M82.3%13.45EUR 2.48MEUR 4.33MEUR 6.21M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-28EUR 162.38M28.51.7%10

Dividend history

Latest trailing dividend snapshot: annual dividend/share 10 EUR, yield 1.8%.

About Limes Schlosskliniken AG

LIMES Schlosskliniken AG operates private clinics for psychiatry, psychotherapy, and psychosomatics services in Germany, Switzerland, Italy, and Liechtenstein. The company focuses on the treatment of stress-related illnesses;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Limes Schlosskliniken AG's market cap?

Limes Schlosskliniken AG's market capitalization is EUR 162.38M.

What is Limes Schlosskliniken AG's P/E ratio?

Limes Schlosskliniken AG's price-to-earnings (P/E) ratio is 28.5.

Does Limes Schlosskliniken AG pay a dividend?

Limes Schlosskliniken AG has a dividend yield of 1.8%.

What does Limes Schlosskliniken AG do?

LIMES Schlosskliniken AG operates private clinics for psychiatry, psychotherapy, and psychosomatics services in Germany, Switzerland, Italy, and Liechtenstein. The company focuses on the treatment of stress-related illnesses; and mental and psychological disorders, such as depression, acute burnout, affective disorders, trauma/PTSD, anxiety disorders, attention deficit hyperactivity disorder, personality disorder, chronic pain, psychoses, obsessive compulsive disorder, sleep disorder, somatoform disorder, and sports psychiatry.